Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
441 to 460 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. | Nat Commun | 2023 | 37607999 | PubTator, text mining | PubMed |
| Current approaches to develop "off-the-shelf" chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review. | Exp Hematol Oncol | 2023 | 37605218 | PubTator, text mining | PubMed |
| Current status of skin cancers with a focus on immunology and immunotherapy. | Cancer Cell Int | 2023 | 37605149 | PubTator, text mining | PubMed |
| Highly Efficient Messenger RNA Transfection of Hard-to-Transfect Cells using Carbon Nanodots. | ACS Omega | 2023 | 37599943 | PubTator, text mining | PubMed |
| Challenges and new technologies in adoptive cell therapy. | J Hematol Oncol | 2023 | 37596653 | PubTator, text mining | PubMed |
| Regulatory T cells targeting a pathogenic MHC class II: Insulin peptide epitope postpone spontaneous autoimmune diabetes. | Front Immunol | 2023 | 37593744 | PubTator, text mining | PubMed |
| Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment. | Mol Ther Oncolytics | 2023 | 37593111 | PubTator, text mining | PubMed |
| Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. | Signal Transduct Target Ther | 2023 | 37591844 | PubTator, text mining | PubMed |
| Eosinophils in the tumor microenvironment: implications for cancer immunotherapy. | J Transl Med | 2023 | 37587450 | PubTator, text mining | PubMed |
| Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin. | J Immunother Cancer | 2023 | 37586774 | PubTator, text mining | PubMed |
| Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models. | J Immunother | 2023 | 37584622 | PubTator, text mining | PubMed |
| Inflammatory myofibroblastic tumor of the distal common bile duct: Literature review with focus on pathological examination. | World J Clin Cases | 2023 | 37584005 | PubTator, text mining | PubMed |
| Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells. | JCI Insight | 2023 | 37581943 | PubTator, text mining | PubMed |
| Developing drugs targeting CX3CL1 to treat heart diseases via immune/inflammatory mediation. | Acta Biochim Biophys Sin (Shanghai) | 2023 | 37580951 | PubTator, text mining | PubMed |
| The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. | Exp Hematol Oncol | 2023 | 37580826 | PubTator, text mining | PubMed |
| Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma. | Blood Adv | 2023 | 37567150 | PubTator, text mining | PubMed |
| Persulfide Biosynthesis Conserved Evolutionarily in All Organisms. | Antioxid Redox Signal | 2023 | 37565274 | PubTator, text mining | PubMed |
| B7-H3 in Brain Malignancies: Immunology and Immunotherapy. | Int J Biol Sci | 2023 | 37564196 | PubTator, text mining | PubMed |
| Chimeric antigen receptor engineered natural killer cells for cancer therapy. | Exp Hematol Oncol | 2023 | 37563648 | PubTator, text mining | PubMed |
| Complementarity-determining region clustering may cause CAR-T cell dysfunction. | Nat Commun | 2023 | 37563127 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=23